| |
|
|
|
Xtalks, Online
2024-10-16
Join our webinar to explore how digital endpoint solutions accelerate breakthroughs in psychiatric drug development. Learn how electronic clinical outcome assessments (eCOA), medical imaging, and cardiac safety monitoring enhance trial accuracy, improve patient experience, and drive innovation in psychiatric clinical trials. Discover the impact of cutting-edge technologies on advancing mental health treatments.
eCOA: As a commonly used primary endpoint in psychiatric drug development, reliable COA data collection is crucial. Attendees will get to learn how common challenges like placebo response, rater drift and poor patient selection can be successfully overcome through the utilization of science-led eCOA and complemented by rater training, in-stream data surveillance and patient education programs
Medical Imaging: Psychiatric drug development requires precise characterization of disease state and its relation to brain biometry and function. Attendees will get to explore how functional magnetic resonance imaging (fMRI) is unlocking insights into brain activation patterns in disorders like major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and schizophrenia, and how specific biomarkers enhance trial design and target engagement.
Cardiac Safety: Many psychiatric therapies have off-target inhibitory effects on cardiac ion channels that produce electrocardiogram (ECG) changes, implicating a risk for proarrhythmia. Understand the importance of 12-lead and continuous ECG monitoring in managing cardiac risks associated with psychiatric therapies, including impacts on blood pressure, and on adverse cardiac events.
By integrating these advanced methodologies, researchers can overcome common challenges, improve data accuracy and enhance decision-making in psychiatric drug development.
The attendees will also get to learn about effective strategies to combat placebo responses and maximize trial success by implementing real-time data surveillance and developing tailored patient education programs to improve participant engagement and compliance.
Register for this webinar today to explore how digital endpoint solutions like eCOA, medical imaging and cardiac safety monitoring are revolutionizing psychiatric drug development.
Keywords: Drug Development, Clinical Research, Biomarkers, PTSD, Clinical Data, eCOA, Schizophrenia, Therapeutic Areas, CNS, Psychiatry, Neuroscience, Major Depressive Disorder, Neuropsychiatry
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
(Moderator) Dr. Todd Rudo, MD, Chief Medical Officer, Clario
Dr. Prateek Verma, MD, Director, eCOA Science & Consulting, Clario
Dave Scott, PhD, Vice President, Medical & Scientific Affairs, Neuroscience, Clario
Dr. Alain Gay, MD, Senior Cardiologist, Cardiology, Clario
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-16
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|